rs10261386 CPED1 diabetes association

Key takeaways

  • rs10261386 is linked to type 2 diabetes with a small effect size p=3e-7 in about 92 people.
  • CPED1 expression is reduced in whole blood, esophagus muscularis and lung.
  • No lifestyle considerations are reported for this variant.

Key takeaways

  • rs10261386 is linked to type 2 diabetes with a small effect size p=3e-7 in about 92 people.
  • CPED1 expression is reduced in whole blood, esophagus muscularis and lung.
  • No lifestyle considerations are reported for this variant.

What the research says A genome-wide association study found rs10261386 is linked to type 2 diabetes with a reported effect size of 6.71 and p=3e-7 in about 92 individuals [PMID 30130595]. Tissue-specific expression analysis shows the CPED1 gene is reduced in whole blood, esophagus muscularis and lung [GTEx Portal].

Reported associations Type 2 diabetes: the variant is associated with a small increase in risk (effect size 6.71 p=3e-7) in about 92 individuals [PMID 30130595].

Evidence quality The GWAS used a small cohort of 92 participants and reported a significant association with type 2 diabetes (p=3e-7). The effect size is modest at 6.71. No other studies are provided in the catalog for this variant.

Tissue-specific expression effects

  • CPED1: reduced expression in whole blood, esophagus muscularis and lung [GTEx Portal].

No lifestyle considerations on file for this variant.

Frequently asked questions

What does the rs10261386 variant do?

It is a genetic change in the CPED1 gene that has been associated with type 2 diabetes. The study reports an effect size of 6.71 and p=3e-7.

Is rs10261386 linked to any other condition?

The evidence only shows a link to type 2 diabetes; no other conditions are reported.

Does the variant affect CPED1 expression in tissues?

Yes, tissue-specific analysis shows reduced expression in whole blood, esophagus muscularis and lung.